Janssen Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis

Janssens Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis

Shots:

  • The P-III DISCOVER 1 & 2 studies results involve assessing of Tremfya vs PBO in 381 & 739 patients with PsA prior treated with anti-TNF biologics & bio-naive candidates respectively
  • The P-III DISCOVER 1 & 2 studies resulted in meeting its 1 EPs @24wks. i.e, improvement in ACR20, no new safety signals are observed
  • Tremfya is a mAb selectively targeting p19 subunit of IL-23 and has received approval in multiple countries including the US, EU, Japan for moderate to severe PsA prior treated with systemic therapies or phototherapy

Click here to read full press release/ article | Ref: Janssen | Image: JNJ Careers – Johnson & Johnson